Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.26
FLDM's Cash-to-Debt is ranked lower than
83% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.32 vs. FLDM: 0.26 )
Ranked among companies with meaningful Cash-to-Debt only.
FLDM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.26  Med: 1.96 Max: No Debt
Current: 0.26
Equity-to-Asset 0.13
FLDM's Equity-to-Asset is ranked lower than
90% of the 216 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. FLDM: 0.13 )
Ranked among companies with meaningful Equity-to-Asset only.
FLDM' s Equity-to-Asset Range Over the Past 10 Years
Min: -7.63  Med: 0.38 Max: 0.89
Current: 0.13
-7.63
0.89
Piotroski F-Score: 1
Altman Z-Score: -2.17
Beneish M-Score: -3.27
WACC vs ROIC
12.05%
-35.14%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -71.16
FLDM's Operating Margin % is ranked lower than
69% of the 221 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. FLDM: -71.16 )
Ranked among companies with meaningful Operating Margin % only.
FLDM' s Operating Margin % Range Over the Past 10 Years
Min: -323.38  Med: -44.12 Max: -26.2
Current: -71.16
-323.38
-26.2
Net Margin % -72.60
FLDM's Net Margin % is ranked lower than
70% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.48 vs. FLDM: -72.60 )
Ranked among companies with meaningful Net Margin % only.
FLDM' s Net Margin % Range Over the Past 10 Years
Min: -349.84  Med: -51.39 Max: -23.22
Current: -72.6
-349.84
-23.22
ROE % -106.87
FLDM's ROE % is ranked lower than
87% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. FLDM: -106.87 )
Ranked among companies with meaningful ROE % only.
FLDM' s ROE % Range Over the Past 10 Years
Min: -90.39  Med: -40.19 Max: -16.77
Current: -106.87
-90.39
-16.77
ROA % -22.68
FLDM's ROA % is ranked lower than
61% of the 237 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.39 vs. FLDM: -22.68 )
Ranked among companies with meaningful ROA % only.
FLDM' s ROA % Range Over the Past 10 Years
Min: -67.71  Med: -32.82 Max: -13.71
Current: -22.68
-67.71
-13.71
ROC (Joel Greenblatt) % -295.82
FLDM's ROC (Joel Greenblatt) % is ranked lower than
72% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.64 vs. FLDM: -295.82 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
FLDM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -448.22  Med: -231.92 Max: -138.28
Current: -295.82
-448.22
-138.28
3-Year Revenue Growth Rate 8.80
FLDM's 3-Year Revenue Growth Rate is ranked higher than
59% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. FLDM: 8.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
FLDM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -40.9 Max: 20.4
Current: 8.8
0
20.4
3-Year EBITDA Growth Rate 53.00
FLDM's 3-Year EBITDA Growth Rate is ranked higher than
92% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.60 vs. FLDM: 53.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
FLDM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -56.65 Max: 53
Current: 53
0
53
3-Year EPS without NRI Growth Rate 59.10
FLDM's 3-Year EPS without NRI Growth Rate is ranked higher than
95% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. FLDM: 59.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
FLDM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -55.3 Max: 59.1
Current: 59.1
0
59.1
GuruFocus has detected 5 Warning Signs with Fluidigm Corp $FLDM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» FLDM's 30-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3826
Compare:NAS:TTOO, NAS:VRML, NAS:CTSO, OTCPK:CBIS, NAS:FLGT, NAS:PMD, AMEX:VNRX, NAS:TRIB, NAS:AIQ, NAS:CEMI, NAS:CGIX, OTCPK:EDTXF, OTCPK:ANPCY, AMEX:PTN, AMEX:SENS, OTCPK:CLIFF, OTCPK:EPGNF, NAS:MGEN, NAS:BIOC, OTCPK:PRFMF » details
Traded in other countries:FLB.Germany,
Headquarter Location:USA
Fluidigm Corp creates, manufactures, and markets technologies and life-science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon microfluidics and mass cytometry technologies.

Fluidigm manufactures life science tools focused on the analysis of single cells and industrial applications of genomics. These tools are based on microfluidics and mass cytometry technologies. Fluidigm sells instruments and consumables, including integrated fluidic circuits, assays, and reagents. Slightly more than half of the firm's revenue comes from the sale of instruments. Fluidigm primarily sells its products to academic institutions, clinical laboratories, and biopharmaceutical companies. The majority of Fluidigm's revenue is generated in the United States and Europe.

Top Ranked Articles about Fluidigm Corp

European Mass Cytometry Consortium Brings CyTOF Technology to Leading Universities to Advance Clinical Research
Fluidigm to Report Q1 2017 Financial Results and Host Conference Call
Nicolas Barthelemy and Carlos Paya Join Fluidigm Board of Directors

SOUTH SAN FRANCISCO, Calif., March 27, 2017 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that Nicolas Barthelemy and Dr. Carlos Paya have been appointed to its Board of Directors.
Barthelemy brings over 25 years of health care industry experience to the Fluidigm Board, having served in multiple senior executive roles in the biopharmaceutical, life science tools, and molecular diagnostics sectors. He previously served as President and CEO of Biotheranostics, a privately held molecular diagnostics company, from 2014 until February 2017. Just prior to that, he served as President of Global Commercial Operations at Life Technologies, a $4 billion life science industry leader that was acquired by Thermo Fisher Scientific in 2014.  Prior to that position, he led the $850 million Cell Systems Division for five years at Life Technologies.  Before Life Technologies, Barthelemy was with Biogen for eight years in operational and commercial roles of increasing responsibility, including Vice President of Manufacturing. He began his career with Merck & Co., Inc. as a Project Engineer in the Vaccine Division. Barthelemy currently also serves on the Board of Directors of Repligen Corporation and he was on the Board of Essen BioScience, a privately held life science company, until its recent acquisition by Sartorius AG.  He received an M.S. in chemical engineering from the University of California, Berkeley, and an engineering degree from Ecole Supérieure de Physique et de Chimie Industrielles in Paris. “I am very excited to be joining Fluidigm at a critical juncture in its history,” said Barthelemy. “Fluidigm is in the middle of a business transformation that requires balancing investments in innovation, commercial execution, and operational excellence.  I share their enthusiasm for building the next generation of automated mass cytometry and genomics workflow solutions for life science and clinical markets.  I see tremendous potential in both areas.” Dr. Paya brings to the Board over 15 years of senior executive experience in the large, mid-cap, and small-cap biopharmaceutical industries, combined with a prolific scientific background and a track record of leading high-impact innovation. Dr. Paya currently serves as President, Chief Executive Officer, and Director of Immune Design Corp., a clinical-stage immunotherapy company focused on oncology. He previously served as President of Elan Corporation, a pharmaceutical corporation later acquired by Perrigo Company, from 2008 to 2011. Before joining Elan Corporation, Dr. Paya was at Eli Lilly & Company from 2001 to 2008 as Vice President of Lilly Research Laboratories. From 1991 to 2001, Dr. Paya was Professor of Medicine, Immunology, and Pathology and Vice Dean of the Clinical Investigation Program at the Mayo Clinic in Rochester, Minnesota. He received his M.D. and Ph.D. degrees from the University of Madrid and underwent postdoctoral training at the Institute Pasteur in Paris. “Fluidigm has breakthrough technologies that will shape how scientific discoveries are developed and applied to human health,” said Dr. Paya. “Joining a company with such a wide portfolio of industry-leading tools and a passion to innovate is a rare opportunity.  In particular, I believe I can help them execute in a manner that reflects the business and scientific needs of oncology.” “We are thrilled to welcome both Nicolas and Carlos to the Fluidigm Board of Directors,” said Christopher Linthwaite, President and CEO of Fluidigm. “Nicolas has a strong track record in driving sustainable growth and business turnarounds. His deep expertise in commercial and operational success in the life sciences industry is particularly relevant to our organizational goals. Carlos is a seasoned CEO, executive leader and world-class researcher with expertise in immunology and oncology. His academic and industrial experiences in these disease research areas are invaluable as we continue to innovate for these high-impact markets. Both of these new members will be instrumental in helping us accelerate several key elements of our business strategy and position the Fluidigm business for long-term success.” About Fluidigm
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single-cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures. We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts. Fluidigm and the Fluidigm logo are registered trademarks of Fluidigm Corporation. Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding changes in operations, development of next-generation products, and the ability of management personnel and our board of directors to contribute to the growth of Fluidigm’s business. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results expressed or implied by these forward-looking statements, including (among others) risks relating to research and development activities and the growth of new and developing markets, Fluidigm’s ability to successfully launch new products and applications, and competition in Fluidigm’s primary markets. Information on these and additional risks, uncertainties, and other information affecting Fluidigm business and operating results are contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2016, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.
Contact:

Fluidigm Corporation
Michaeline Bunting
Sr. Director, Marketing
Fluidigm Corporation
650 737 4190
[email protected]

Read more...
Columbia Wanger Sold 2 Stakes in September Divested holdings were in diagnostics and research industry
Columbia Wanger (Trades, Portfolio) sold two stakes from its portfolio on Sept. 30. Read more...

Ratios

vs
industry
vs
history
PB Ratio 2.97
FLDM's PB Ratio is ranked higher than
66% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.75 vs. FLDM: 2.97 )
Ranked among companies with meaningful PB Ratio only.
FLDM' s PB Ratio Range Over the Past 10 Years
Min: 1.46  Med: 4.62 Max: 12.54
Current: 2.97
1.46
12.54
PS Ratio 1.12
FLDM's PS Ratio is ranked higher than
86% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.61 vs. FLDM: 1.12 )
Ranked among companies with meaningful PS Ratio only.
FLDM' s PS Ratio Range Over the Past 10 Years
Min: 0.94  Med: 5.94 Max: 16.78
Current: 1.12
0.94
16.78
Current Ratio 2.75
FLDM's Current Ratio is ranked higher than
51% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.72 vs. FLDM: 2.75 )
Ranked among companies with meaningful Current Ratio only.
FLDM' s Current Ratio Range Over the Past 10 Years
Min: 1.13  Med: 4.56 Max: 8.73
Current: 2.75
1.13
8.73
Quick Ratio 2.12
FLDM's Quick Ratio is ranked higher than
50% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. FLDM: 2.12 )
Ranked among companies with meaningful Quick Ratio only.
FLDM' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 4.07 Max: 8.11
Current: 2.12
0.86
8.11
Days Inventory 156.20
FLDM's Days Inventory is ranked lower than
76% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 82.10 vs. FLDM: 156.20 )
Ranked among companies with meaningful Days Inventory only.
FLDM' s Days Inventory Range Over the Past 10 Years
Min: 102.81  Med: 149.83 Max: 443.32
Current: 156.2
102.81
443.32
Days Sales Outstanding 52.02
FLDM's Days Sales Outstanding is ranked higher than
64% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.14 vs. FLDM: 52.02 )
Ranked among companies with meaningful Days Sales Outstanding only.
FLDM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 51.06  Med: 84.55 Max: 124.82
Current: 52.02
51.06
124.82
Days Payable 29.61
FLDM's Days Payable is ranked lower than
79% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 58.94 vs. FLDM: 29.61 )
Ranked among companies with meaningful Days Payable only.
FLDM' s Days Payable Range Over the Past 10 Years
Min: 31.47  Med: 74.66 Max: 283.05
Current: 29.61
31.47
283.05

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.10
FLDM's 3-Year Average Share Buyback Ratio is ranked higher than
59% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. FLDM: -4.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
FLDM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -143.7  Med: -8.2 Max: 0
Current: -4.1
-143.7
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.19
FLDM's Price-to-Median-PS-Value is ranked higher than
95% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. FLDM: 0.19 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
FLDM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.16  Med: 1.02 Max: 2.34
Current: 0.19
0.16
2.34
Earnings Yield (Greenblatt) % -28.09
FLDM's Earnings Yield (Greenblatt) % is ranked lower than
85% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.52 vs. FLDM: -28.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
FLDM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -28.9  Med: -7 Max: -1.5
Current: -28.09
-28.9
-1.5

More Statistics

Revenue (TTM) (Mil) $100.98
EPS (TTM) $ -2.52
Beta4.26
Short Percentage of Float15.12%
52-Week Range $3.54 - 10.94
Shares Outstanding (Mil)29.30
» More Articles for FLDM

Headlines

Articles On GuruFocus.com
European Mass Cytometry Consortium Brings CyTOF Technology to Leading Universities to Advance Clinic May 04 2017 
Fluidigm to Report Q1 2017 Financial Results and Host Conference Call Apr 20 2017 
Nicolas Barthelemy and Carlos Paya Join Fluidigm Board of Directors Mar 27 2017 
Columbia Wanger Sold 2 Stakes in September Oct 07 2016 

More From Other Websites
ETFs with exposure to Fluidigm Corp. : June 16, 2017 Jun 16 2017
Edited Transcript of FLDM earnings conference call or presentation 4-May-17 9:00pm GMT May 23 2017
ETFs with exposure to Fluidigm Corp. : May 15, 2017 May 15 2017
Fluidigm Corp. :FLDM-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 May 12 2017
Fluidigm reports 1Q loss May 05 2017
European Mass Cytometry Consortium Brings CyTOF Technology to Leading Universities to Advance... May 04 2017
Fluidigm Announces First Quarter Financial Results May 04 2017
Investor Network: Fluidigm Corporation to Host Earnings Call May 04 2017
Cerner (CERN) Earnings and Revenues Beat Estimates in Q1 Apr 28 2017
CONMED (CNMD) Q1 Earnings Surpass Estimates, Increase Y/Y Apr 27 2017
Fluidigm to Report Q1 2017 Financial Results and Host Conference Call Apr 20 2017
Becton (BDX) Gets FDA 510(k) for New Flow Cytometer System Apr 07 2017
Fresenius (FMS) Acquires 70% Stake in Kunming Wuhua Hospital Apr 07 2017
Mazor Expects Higher Q1 Revenue, Receives Mazor X Orders Apr 06 2017
Teleflex (TFX) Acquires Medical Device Provider Pyng Medical Apr 05 2017
Becton, Dickinson Takes Over Caesarea Medical Electronics Apr 05 2017
Varian (VAR) Eclipse Software Tops in International Studies Apr 03 2017
PAREXEL (PRXL) Launches Sensor for Clinical Trial Market Mar 31 2017
AngioDynamics (ANGO) Beats on Q3 Earnings, Raises 2017 View Mar 31 2017
Merit Medical (MMSI) Closes 5.2M Follow-On Share Offering Mar 30 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}